Resolute Advisors’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-22,800
Closed -$321 – 75
2023
Q4
$321 Buy
+22,800
New +$321 ﹤0.01% 73
2023
Q3
– Sell
-22,800
Closed -$545 – 69
2023
Q2
$545 Hold
22,800
– – ﹤0.01% 65
2023
Q1
$5.24K Hold
22,800
– – ﹤0.01% 71
2022
Q4
$2.53K Hold
22,800
– – ﹤0.01% 60
2022
Q3
$24K Hold
22,800
– – ﹤0.01% 96
2022
Q2
$42K Hold
22,800
– – ﹤0.01% 77
2022
Q1
$81K Hold
22,800
– – ﹤0.01% 70
2021
Q4
$196K Hold
22,800
– – 0.01% 61
2021
Q3
$173K Buy
+22,800
New +$192K 0.02% 70

Resolute Advisors's LHDX Position: Q1 2024 in Review

Resolute Advisors sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2024, closing a stake of 22,800 shares — an estimated $321 sold.

Resolute Advisors first reported a position in LHDX in Q3 2021 and held it in 9 quarters. The position peaked at $196K in Q4 2021. 0 funds tracked by Wall St. Rank hold LHDX as of Q1 2024.

  • Resolute Advisors reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Resolute Advisors sold 22,800 Lucira Health, Inc. Common Stock shares in Q1 2024, an estimated $321.
  • Resolute Advisors first reported a position in Lucira Health, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
  • Resolute Advisors's Lucira Health, Inc. Common Stock position peaked at $196K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2024.

Based on Resolute Advisors's 13F filing for Q1 2024, filed 10 May 2024.